Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MedMira Inc MMIRF


Primary Symbol: V.MIR

Healthcare Medical Devices
MedMira Inc. is a Canada-based biotechnology company. The Company, through its subsidiaries, is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company invests in research in order to maintain and expand its position in the global diagnostics market. Its research is focused on specific areas of the broader diagnostics market, namely... see more

Recent & Breaking News (TSXV:MIR)

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

Accesswire January 11, 2023

Point-of-Care Diagnostic for Trichomonas Vaginalis Based on MedMira's RVF Technology(R)

Accesswire January 3, 2023

MedMira Reports First Quarter Results FY2023

Accesswire December 30, 2022

MedMira Introduces VYRA TriDemic

Accesswire December 29, 2022

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

Accesswire November 29, 2022

MedMira (TSXV:MIR) receives CE mark for its VYRA COVID-19 Antigen Test

John Ballem  October 14, 2022

MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test

Accesswire October 14, 2022

MedMira (TSXV:MIR) provides progress update

Caroline Egan  October 3, 2022

MedMira provides Progress Update

TheNewsWire October 3, 2022

MedMira provides Progress Update

TheNewsWire October 3, 2022

MedMira Strengthens and Expands Board

GlobeNewswire July 14, 2022

MedMira Reports Third Quarter Results FY2022

GlobeNewswire June 29, 2022

MedMira (TSXV:MIR) receives patent for its quantitative diagnostic system

Azuka Onwuka June 6, 2022

MedMira Receives Patent for its Unique Quantitative Diagnostic System

GlobeNewswire June 6, 2022

MedMira (TSXV:MIR) gets CE mark during new device regulations

Caroline Egan  May 27, 2022

MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market

GlobeNewswire May 27, 2022

VYRA(TM) Product Line Update

GlobeNewswire May 20, 2022

MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test

GlobeNewswire May 12, 2022

MedMira Reports Second Quarter Results FY2022

Business Wire March 31, 2022

MedMira (TSXV:MIR) receives the CE mark for its STI treatment and starts clinical trials in Canada

Caroline Egan  March 9, 2022